Search
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalIt is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing … [L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. … potentially beneficial synergistic effects in treating chronic Hepatitis D, bulevirtide is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With [Peginterferon Alfa-2a
Nelistotug
go.drugbank.com/drugs/DB19334InvestigationalNelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous
Ancitabine
go.drugbank.com/drugs/DB20595ExperimentalAncitabine has a monoisotopic molecular weight of 225.07 Da. … Ancitabine is a small molecule drug.
Galocitabine
go.drugbank.com/drugs/DB21373ExperimentalGalocitabine has a monoisotopic molecular weight of 439.14 Da. … Galocitabine is a small molecule drug.
Alpibectir
go.drugbank.com/drugs/DB21561InvestigationalAlpibectir has a monoisotopic molecular weight of 332.1 Da. … Alpibectir is a small molecule drug.
Ceperognastat
go.drugbank.com/drugs/DB21591InvestigationalCeperognastat has a monoisotopic molecular weight of 383.14 Da. … Ceperognastat is a small molecule drug.
Ranosidenib
go.drugbank.com/drugs/DB21727InvestigationalRanosidenib has a monoisotopic molecular weight of 453.12 Da. … Ranosidenib is a small molecule drug. Ranosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia).
CoVac-1
go.drugbank.com/drugs/DB16429InvestigationalSponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].
Imalumab
go.drugbank.com/drugs/DB15558InvestigationalImalumab is under investigation in clinical trial NCT02540356 (Phase 1/2a Two-arm Dose-escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer).